Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely

It’s not realistic to expect sudden changes in US agency’s regulation of medical product communications to healthcare providers and payers given the other pressing issues facing new Commissioner Scott Gottlieb, Medical Information Working Group’s Klasmeier says.